Costimulatory blockade via the CTLA-4–Ig fusion protein abatacept is beneficial in patients with early-onset type 1 diabetes, but some individuals benefit more than others. A new study reports that the pretreatment abundance of T follicular helper (TFH) cells could predict clinical responses to abatacept.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Orban, T. et al. Lancet 378, 412–419 (2011).
Orban, T. et al. Diabetes Care 37, 1069–1075 (2014).
Edner, N. M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-0744-z (2020).
Crotty, S. Immunity 50, 1132–1148 (2019).
Ziegler, A. G. et al. JAMA 309, 2473–2479 (2013).
Kenefeck, R. et al. J. Clin. Invest. 125, 292–303 (2015).
Viisanen, T. et al. Diabetes 66, 437–447 (2017).
Ferreira, R. C. et al. Diabetologia 58, 781–790 (2015).
Verstappen, G. M. et al. Arthritis Rheumatol. 69, 1850–1861 (2017).
Fukuyo, S. et al. Clin. Exp. Rheumatol. 35, 562–570 (2017).
Wang, C. J. et al. Proc. Natl Acad. Sci. USA 112, 524–529 (2015).
Glatigny, S. et al. J. Immunol. 202, 1373–1382 (2019).
Linsley, P. S., Greenbaum, C. J., Speake, C., Long, S. A. & Dufort, M. J. JCI Insight 4, e126136 (2019).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Bettelli, E., Campbell, D.J. Circulating TFH cells as a marker for early therapeutic intervention in T1D. Nat Immunol 21, 1141–1142 (2020). https://doi.org/10.1038/s41590-020-0766-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-020-0766-6